Pregunta o busca lo que quieras...
Investigación destacada hoy
Artículos de todas las revistas, en un solo lugar. Crea feeds personalizados.
2d ago
Comentario expertoDestacado en Circulation
Level 1: Clinical Guideline
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
Implicación
Standardizes pre-HF identification to enable targeted prevention; extends 2021 consensus for consistent research and surveillance.
Circulation
1w ago
Comentario expertoDestacado en Circulation
Level 1: Clinical Guideline
Strategies for Optimizing Heart Failure Care in the Older Adult: A Scientific Statement From the American Heart Association
Implicación
Tailored plans needed to improve GDMT access in older HF patients; extends recommendations to address age-specific barriers.
Circulation
2w agoOpen Access
Comentario expertoDestacado en ACC Journal Scan
Level 2: RCT
Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy
Aficamten monotherapy improves submaximal exercise VE/VCO2 slope by ~2.8 points vs metoprolol in symptomatic oHCM.
Implicación
Aficamten may be preferred over metoprolol for exercise capacity in symptomatic obstructive HCM; extends RCT evidence for myosin inhibitors versus beta-blockade.
““These findings provide compelling justification for aficamten treatment as an appropriate alternative to current first-line treatment with metoprolol, to treat exercise intolerance in oHCM.””
— ACC Journal ScanVer fuente
JAMA Cardiology
Harvard University
1w agoOpen Access
Comentario expertoDestacado en Circulation
Level 1: Clinical Guideline
Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association
Implicación
May inform perinatal HF care via expert consensus; leaves open standardized definitions and screening tools.
Circulation
1w agoOpen Access
Tendencia en XTendencia en XComentario expertoDestacado en ACC Journal Scan
Level 2: RCT
Seven-Year Valve Durability With Transcatheter or Surgical Aortic Valve Replacement
TAVR shows similar 7-year rates of stage 2 or 3 SVD versus surgery in low-risk patients.
Implicación
Supports comparable midterm valve durability for TAVR and surgery; leaves open need for extended follow-up data.
“For now, the PARTNER 3 trial durability analysis offers reassuring evidence of excellent midterm outcomes in low-risk patients. As TAVR continues to move into younger populations, understanding which durability pathways matter, and in whom, will be key to building effective lifetime valve strateg...”
— ACC Journal ScanVer fuente
JAMA Cardiology
University of Pennsylvania
4w agoOpen Access
Destacado en podcastComentario expertoDestacado en ACC Journal Scan
Level 2: RCT
10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis
TAVR with SAPIEN XT increases 10-year all-cause mortality ~13% versus surgery.
Implicación
May favor surgery over early-generation TAVR for 10-year survival in intermediate-risk patients; challenges assumptions of long-term equivalence.
“Taken together, the studies show a likely early advantage of TAVR with respect to the important primary clinical endpoints, with a later catch-up of surgery, such that there are no major differences between the therapies at 5 years.”
— Dr. Tamim NazifVer fuente
Journal of the American College of Cardiology
Stanford University
3w ago
Comentario expertoDestacado en podcastDestacado en Circulation
Level 1: Clinical Guideline
Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology
Implicación
Scientific statement examines risk assessment for improving cardiovascular disease prevention strategies.
Circulation
4w agoOpen Access
Destacado en podcastComentario expertoDestacado en ACC Journal Scan
Level 3: Cohort Study
10-Year Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement or Surgery in Intermediate-Risk Patients
TAVR shows similar 10-year all-cause mortality to surgery in intermediate-risk patients.
Implicación
Supports TAVR durability in intermediate-risk patients; extends PARTNER 2 follow-up yet leaves open need for randomized confirmation.
“Taken together, the studies show a likely early advantage of TAVR with respect to the important primary clinical endpoints, with a later catch-up of surgery, such that there are no major differences between the therapies at 5 years. However, we know that 6 to 10 years and beyond is really the test of time for these valves, and that’s where we’re starting to see some differences emerge.”
— Dr. Tamim NazifVer fuente
Journal of the American College of Cardiology
Stanford University
4w ago
Tendencia en XComentario expertoDestacado en ACC Journal Scan
Level 3: Cohort Study
Resistance Training, Aerobic Activity, Television Viewing, and Risk of Major Cardiovascular Events in U.S. Women
Resistance training ≥2 hours weekly in women linked to ~20% lower major CVD risk.
Implicación
Observational data should not yet change practice; extends evidence on resistance training for CVD prevention in women but requires trials.
“These findings suggest that, within an already active population, RT is associated with additional reductions in [cardiovascular disease] risk above and beyond overall aerobic activity. Alongside aerobic activity and reductions in sedentary behavior, RT may be an important component of public hea...”
— ACC Journal ScanVer fuente
Journal of the American College of Cardiology
Harvard University
2w ago
Destacado en Circulation
Level 1: Clinical Guideline
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association
Implicación
May enhance CV endpoint consistency in oncology trials; leaves open effects on outcomes or regulatory decisions pending validation.
Circulation
